Celldex Therapeutics, Inc. CLDX

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
28/100
Developing

Ranked against 712 peers in Biotechnology

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and … Full CLDX analysis →

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 0.81), providing operational cushion.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 3.1th percentile with high volatility suggests weak pricing power or commoditized products.
  • Scale Without Profitability Despite scale, profitability lags peers (score 0.08), suggesting limited competitive advantage.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
12
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where CLDX ranks in Biotechnology

Celldex Therapeutics, Inc. ranks #538 of 713 scored companies in Biotechnology by moat score — the top 75%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
534 Telomir Pharmaceuticals, Inc. TELO 28/100 Developing
535 Viracta Therapeutics, Inc. VIRX 28/100 Developing
536 Mereo BioPharma Group plc MREO 28/100 Developing
537 Armata Pharmaceuticals, Inc. ARMP 28/100 Developing
538 Celldex Therapeutics, Inc. CLDX 28/100 Developing
539 Cardio Diagnostics Holdings Inc CDIO 27/100 Developing
540 Cardio Diagnostics Holdings, Inc. CDIOW 27/100 Developing
541 iBio, Inc. IBIO 27/100 Developing
542 Adverum Biotechnologies, Inc. ADVM 27/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How CLDX scores on the Corporate Default defenses

Pricing Power

Score 12 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 13 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 28 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 48 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 52 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 10 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding CLDX's moat

What is Celldex Therapeutics, Inc.'s moat score?

Celldex Therapeutics, Inc. (CLDX) scores 28 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #538 of 713 scored companies in Biotechnology, the top 75%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (52/100) and its weakest is Scale & Market Position (10/100).

How does Celldex Therapeutics, Inc. compare with other Biotechnology companies?

Celldex Therapeutics, Inc. ranks #538 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Armata Pharmaceuticals, Inc. (ARMP) at 28 just above it and Cardio Diagnostics Holdings Inc (CDIO) at 27 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Celldex Therapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Celldex Therapeutics, Inc.?

The Corporate Default template measures 6 defenses, and CLDX scores: Pricing Power (12), Cost Advantage (13), Customer Stickiness (28), Capital Efficiency (48), Resilience (52), Scale & Market Position (10). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000